On 8 January 2013, Amarantus Bioscience, Inc. released the data developed from its research grant from the Michael J. Fox Foundation. The data was presented by the Company’s Chief Science Officer, Dr. John W. Commissiong, at the OneMed 2013 Forum.
There are currently more than 6 million Parkinson’s disease patients worldwide, and that number is expected to double by 2032. Amarantus’ lead drug candidate, MANF (Mesencephalic Astrocyte-Derived Neurothrophic Factor) is an anti-apoptratic therapeutic protein, which the research data demonstrates, provides promising Parkinson’s disease treatment.
Parkinson’s Disease is believed to be caused by a decrease in dopamine in the substantia nigra area of the brain. Independent studies, which were partially funded by a research grant from the Michael J. Fox Foundation for Parkinson’s disease, demonstrate MANF increases the density of DA (dopaminergic neurons) terminals and the concentration of dopamine in the striatum whereas GDNF (Glial Cell-Line Derived Neurotrophic Factor), another drug candidate for the treatment of Parkinson’s disease, does not. Other independent studies conducted under the grant at the UCLA Medical School demonstrate that MANF significantly reduces behavioral deficits associated with Parkinson’s disease whereas GDNF does not.
News 
Market Data 
Discover 
AI
